Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety Panel Urges New Entity To Oversee Japan Drug Approvals

This article was originally published in PharmAsia News

Executive Summary

TOKYO - An ad hoc study commission debating prevention of recurring drug-induced hepatitis and HIV infections has recommended creating an independent entity that would supervise pharmaceutical approvals, drug safety and adverse events in an effort to toughen Japanese new drug approval processes
Advertisement

Related Content

Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
India Price Regulator Wants At Least Five Drug Makers Charged
Advertisement
UsernamePublicRestriction

Register

SC071489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel